التفاصيل البيبلوغرافية
| العنوان: |
L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease. |
| المؤلفون: |
Kanaoka, Tomohiko, Tamura, Kouichi, Wakui, Hiromichi, Ohsawa, Masato, Azushima, Kengo, Uneda, Kazushi, Kobayashi, Ryu, Fujikawa, Tetsuya, Tsurumi-Ikeya, Yuko, Maeda, Akinobu, Yanagi, Mai, Toya, Yoshiyuki, Umemura, Satoshi |
| المصدر: |
International Journal of Molecular Sciences; Aug2013, Vol. 14 Issue 8, p16866-16881, 16p, 6 Charts, 1 Graph |
| مصطلحات موضوعية: |
CARDIAC hypertrophy, HEART diseases, THERAPEUTICS, HYPERTENSION, KIDNEY diseases, CALCIUM antagonists, RENIN-angiotensin system, BLOOD pressure, HEART rate monitoring |
| مستخلص: |
Ambulatory blood pressure (BP) and heart rate (HR) profile are proposed to be related to renal deterioration and cardiovascular complication in hypertension and chronic kidney disease (CKD). In this study, we examined the beneficial effects cilnidipine, a unique L/N-type calcium channel blocker (CCB), in addition to renin-angiotensin system inhibitors, on ambulatory BP and HR profile, as well as cardiorenal function in hypertensive CKD patients. Forty-five patients were randomly assigned to the cilnidipine replacement group (n = 21) or the control CCBs group (n = 24) during a 24-week active treatment period. Although clinical BP values were similar in the cilnidipine and control CCBs groups after the treatment period, the results of ambulatory BP monitoring showed that the 24-h and daytime systolic BP levels in the cilnidipine group were significantly lower compared with the control group after the study. Furthermore, the left ventricular mass index (LVMI) was significantly decreased in the cilnidipine group compared to the control group after the study (LVMI, 135.3 ± 26.4 versus 181.2 ± 88.4, p = 0.031), with a significant difference in the changes in the LVMI between the cilnidipine and control groups (change in LVMI, -12.4 ± 23.7 versus 26.2 ± 64.4, p = 0.007). These results indicate that cilnidipine is beneficial for the suppression of pathological cardiac remodeling, at least partly, via a superior improving effect on ambulatory BP profile compared with control CCBs in hypertensive CKD patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of International Journal of Molecular Sciences is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder